Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 409-411
DOI: 10.4103/ijmpo.ijmpo_147_18
Practitioner Section

A Report of a Rare Case of Hurthle Cell Carcinoma of Thyroid with Metachronous Renal Metastasis

Ritesh Kumar
Department of Radiation Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Rituparna Biswas
Department of Radiation Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Sandeep Mathur
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Suman Bhasker
Department of Radiation Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Nishikant Damle
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
,
CS Bal
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
,
Ekta Dhamija
Department of Radiology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Renal metastasis from Hurthle cell thyroid carcinoma is an extremely rare phenomenon which when present usually indicates widely disseminated disease. Herein, we present a case of Hurthle cell carcinoma of thyroid in a 58-year-old gentle lady, with metachronous renal metastasis which happens to be the fourth reported case in English literature.

Keywords

Follicular carcinoma - Hurthle cell - renal metastasis - thyroid malignancies


Publication History

Received: 06 July 2018

Accepted: 12 September 2018

Article published online:
28 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg 2003; 129: 207-10
    CrossrefPubMedGoogle Scholar
  • 2 Djekidel M, Gordon M, Shah RB, Gross MD, Avram A. Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging. Thyroid 2010; 20: 429-33
    CrossrefPubMedGoogle Scholar
  • 3 Zhang H, Zeng L, Liang C, Qiu H, Zhang M, Zhu Y. et al. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol 2012; 42: 1086-90
    CrossrefPubMedGoogle Scholar
  • 4 Claimon M, Suh M, Cheon GJ, Lee DS, Kim EE, Chung JK. et al. Bilateral renal metastasis of Hürthle cell thyroid cancer with discordant uptake between I-131 sodium iodide and F-18 FDG. Nucl Med Mol Imaging 2017; 51: 256-60
    CrossrefPubMedGoogle Scholar
  • 5 Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. et al. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: A single-institution experience. BMC Cancer 2016; 16: 162
    CrossrefPubMedGoogle Scholar
  • 6 Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg 2004; 28: 1266-70
    CrossrefPubMedGoogle Scholar
  • 7 Watson RG, Brennan MD, Goellner JR, van Heerden JR, McConahey WM, Taylor WF. et al. Invasive Hürthle cell carcinoma of the thyroid: Natural history and management. Mayo Clin Proc 1984; 59: 851-5
    CrossrefPubMedGoogle Scholar
  • 8 Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG. et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer 2003; 97: 1186-94
    CrossrefPubMedGoogle Scholar
  • 9 Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013; 34: 439-55
    CrossrefPubMedGoogle Scholar